Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
239.94-3.29 (-1.35%)
At close: 4:00PM EST
240.00 +0.06 (0.03%)
Pre-market: 6:09AM EST
| Previous close | 243.23 |
| Open | 243.90 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 900 |
| Day's range | 234.21 - 247.74 |
| 52-week range | 6.77 - 331.68 |
| Volume | 1,668,420 |
| Avg. volume | 5,121,295 |
| Market cap | 16.138B |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.66 |
| Earnings date | 01 Mar 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 253.75 |
- Motley Fool
Is Novavax Stock a Buy?
Novavax (NASDAQ: NVAX) is one stock that I made the right call on; it's been a huge winner. As far back as March 2018, I wrote that "if you're willing to take on risk, buying a small position in Novavax could pay off in a big way." Throughout 2020, I sang Novavax's praises.
- Motley Fool
Here Are the 2 Most Important Things to Look for in Novavax's Earnings Report Next Week
Novavax doesn't have products on the market yet, which means the biotech company is yet to report an annual profit. Novavax recently reported U.K. phase 3 trial results and just completed enrollment in a U.S. phase 3 trial. Possible regulatory authorizations sit on the horizon.
- Yahoo Finance
COVID-19 vaccine manufacturing is improving, executives tell Congress
Executives from vaccine companies testified before House subcomittee on progress and hurdles in manufacturing vaccines.
© 2021 Verizon Media. All rights reserved.
